In JAMA: Patient Perspectives on Approval Speed vs. Evidentiary Certainty in US Cancer Drug Approvals

Your gift is doubled through December 31.

Donate Now

How do patients feel about speedy drug approvals vs. more evidence to support a new treatment’s effectiveness?

A new JAMA publication, coauthored by NBCC’s Chief Programs Officer Michelle Tregear and Chief Policy Officer Melanie Wyne, explores breast cancer patients’ views on the trade-offs between faster approval and the evidentiary certainty of new cancer drugs in the US.

The findings show that:

For many participants, additional uncertainty about clinical benefit was an acceptable trade-off for faster approval when facing end-of-life decisions, when no alternative treatment options existed, or when the anticipated benefit of a new drug was transformative…

However, at earlier stages of disease, when treatment options are available, or when the anticipated benefit of a new drug may only be marginal, participants suggested that greater certainty should often take priority over speed.

A common belief among participants: overall survival and quality of life are the most meaningful treatment outcomes.

You do have to see if [a new drug] is going to extend life, and that takes time. There’s no way that you can step around that.

Am I still able to walk? Am I still able to eat, able to dress myself, able to move around independently…those are pretty important to me.

You can keep me alive for another 6 years, but if I can’t get on the ground and play with my grandchildren, or I can’t, you know, go for a walk with my husband, it’s really not worth it.

Related News